The coronavirus disease 2019 (COVID-19) outbreak substantially reduced cancer clinical trial accrual.1 Many sites temporarily paused enrollment owing to state, local, sponsor, or institutional restrictions intended to prevent the spread of COVID-19.2 Once site and enrollment restrictions lift, it is unclear whether patients will be as willing to participate in clinical research as before the outbreak, especially if community COVID-19 transmission is still occurring. To examine this, we surveyed a large group of cancer survivors about their attitudes toward trial participation during the COVID-19 pandemic.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Fleury ME, Farner AM, Unger JM. Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials. JAMA Oncol. 2021;7(1):131–132. doi:10.1001/jamaoncol.2020.5748
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: